Syros Pharmaceuticals (SYRS) Tops Q2 EPS by 1c

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q2 EPS of ($0.36), $0.01 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $5.1 million versus the consensus estimate of $4.13 million.

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.

You May Also Be Interested In

• Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
• BofA Securities Downgrades Logitech International SA (LOGN:SW) (LOGI) to Underperform
• Canaccord Starts Regal Partners Ltd (RPL:AU) at Buy